1.Association between Human Leukocyte Antigen DR gene polymorphisms and total IgE levels in children with asthma
Qingling XIE ; Hong ZHEN ; Ling QIN
Clinical Medicine of China 2012;28(6):597-600
Objective To investigate the association between Human Leukocyte Antigen DR (HLADR) gene polymorphisms and total IgE levels in children with asthma.Methods This study involved 84 unrelated children with asthma and 168 healthy controls without asthma.All participants had their serum total IgE levels measured with UniCAP Pharmacia system,and skin-prick test with ten kinds of inhalant allergens were taken among them.HLA oligonucleotide array was used to determine twenty-one gene frequencies of HLADR.Results ( 1 ) The frequencies of HLA-DRB1 * 070X allele and HLA-DRB1 * 11XX allele among the asthmatic were significantly higher than those in the healthy controls (HLA-DRB1 * 070X allele:2.98%vs.0.30%,x2 =6.915,P < 0.05 ; HLA-DRB1 * 11XX allele:13.69% vs.5.95%,x2 =9.478,P < 0.01 ),Odds ratios( OR)for the two groups were 10.57(95% CI:1.215 -91.986)and 2.79(95% CI:1.429 -5.449)respectively.HLA-DRB3( 52 ) * 010X allele were significantly decreased in asthmatics compared to healthy controls(13.99%,x2 =5.854,P <0.05),OR was 0.429(95% CI:0.214 -0.862).(2) Significant correlation between HLA-DRB1 * 160XX,HLA-DRB1 * 3 (17)alleles and the level of total IgE were found in asthmatic children(P <0.05).OR were 0.145(95% CI:0.027 -0.781 )for HLA-DRB1 * 160XX allele and 1.667(95%CI:1.367-2.033)for HLA-DRB1 * 3(17)allele.Conclusion HLA-DRB1 *070X allele and HLA-DRB1 * 11XX allele were implicated in susceptibility to asthma,HLA-DRB3 (52) * 010X allele might conferring protection effects against asthma.There were association between HLA-DRB1 * 160XX,HLA-DRB1 * 3 ( 17 ) alleles and the level of total IgE in asthmatic children.Protective effects of HLA-DRB1 * 160XX allele against high level IgE response was noted,while HLA-DRB1 * 3(17)allele might be associated with high level of IgE in patients with asthma.
2.The extraction of fat from scallop viscera gland and the analysis of the fatty acids
Qingling XU ; Qingzhu ZENG ; Zhifen XIE ;
Chinese Journal of Marine Drugs 1994;0(01):-
The extraction of the fatty acids from viscera gland of Chlamys farreri and Pecten yesoensis cultured off shore Dalian was studied and the fatty acids in fat were analysis.The results show that extraction rate,3.01%,is the highest when gas(CO 2) is filled up to expel oxygen,the ratio of material to water is 1∶2,the time is 60 minuites and temperature is 100℃.The contents of the unsaturated fatty acids of viscera gland fatty acids in Chlamys farreri and Pecten yesoensis are 32.0% and 32.8% respectively,in which the contents of EPT+DHA are 13.6% and 13.8% respectively.
3.Correlation between multiple blood factors and severity of coronary atherosclerosis on 320 slice dynamic volume computed tomography
Qingling LI ; Ruomi GUO ; Wenying ZHOU ; Dielai XIE ; Zhuang KANG ; Xiaoming YE ; Yan ZOU
Journal of Practical Radiology 2017;33(6):603-606
Objective To evaluate the clinical value of hs-CRP,Tbil and BUA in the diagnosis of coronary atherosclerosis on 320 slice dynamic volume computed tomography(320-DVCT).Methods 160 patients with stable angina pectoris were included.All patients underwent 320-DVCT coronary artery imaging and laboratory testing including plasma hs-CRP,Tbil and BUA.The plaques of coronary artery were classified as soft plaque,fibrous plaque and calcified plaque on CT values.The three indicators were used to confirm the ability of diagnosis on number of lesions,plaque character and the degree of stenosis.100 healthy persons served as the control group.Results With the concentration of hs-CRP,BUA increased and Tbil concentration decreased,the number and the stenosis degree of coronary lesions became increased,and easier to form a soft plaque.Conclusion The hs CRP,Tbil and BUA can offer the accurate diagnosis of lesions number,plaque character and stenosis degree of the coronary artery,which is showed on 320-DVCT.The hs-CRP,Tbil and BUA are conducive to the risk assessment of coronary atherosclerosis.
4.Diagnosis and treatment of perirenal hematoma associated with ureteral flexible lithotripsy
Tian LI ; Xiangzhou SUN ; Xun LI ; Yongzhong HE ; Dehui LAI ; Weiqing YANG ; Qingling XIE
The Journal of Practical Medicine 2017;33(5):756-758
Objective To explore the risk factors ,prevention and treatment of the occurrence of perirenal hematoma after flexible lithotripsy. Methods We retrospectively analyzed the clinical data of 18 patients with symptomatic perirenal hematoma from 1259 who had undergone ureteral flexible lithotripsy in our hospital during the period of April 2007 to April 2016. Of the 18 patients,7 were complicated with diabetes mellitus,11 had urinary tract infection;15 were female,and 3 were male. Results Perirenal hematoma was confirmed by B ultrasound and CT,which situated on the Posterolateral side of the kidney in 8 patients,and on the lower pole and abdominal side in 10. Hematoma depth was 2.6-15.3 cm(average was 5.2 cm). The hematoma?related symptoms gradually disappeared in 11 patients 7 to 14 days after they received conservative treatment. 5 recovered gradually 15 days after undergoing hematoma puncture and drainage ,and 2 recovered 36 days after receiving open surgery for removal of hematoma. Conclusions Female,diabetes,urinary tract infection,bigger stone size,prolonged surgical duration,and infected stones were the risk factors for perinephric hematoma related to ureteroscopic lithotripsy. Full preoperative preparation ,effective anti?infection ,intraoperative improvement of calculus?breaking skills and use of large caliber semirigid through sheath,low pressure perfusion,shorter surgical duration,and staging surgery are effective ways to reduce the occurrence of perirenal hematoma.
5.Establishment of eosinophilic bronchitis mice model without airway hyperresponsiveness
Jiaxing XIE ; Qingling ZHANG ; Liyan CHEN ; Wei LUO ; Kefang LAI ; Nanshan ZHONG
Journal of Chinese Physician 2014;(7):882-885
Objectiev To explore the use of different nebulizer to establish mice model that have airway eosinophilic inflam -mation without airway hyperresponsiveness .Methods Female BALB/c mice were obtained and divided randomly into 3 groups:eo-sinophilic airway inflammation group ( experimental group ) , asthma group, and control group .Mice were immunized with ovalbumin ( OVA) .The experiment group and asthma group were challenged with an aerosol of 1% w/v OVA using a PARI TIA and PARI LC STAR nebulizer on day 28, 29, 30, respectively.The control mice were received saline sensitization and challenge .Airway respon-siveness was measured .Cell different counts in bronchial alveolus lavage fluid ( BALF) were performed and a pathologist performed histopathological evaluation of the trachea and lung .Results Airway responsiveness in the experimental group was not significantly different compared with the normal saline ( NS) group but was significantly different compared with the asthma group .Eosinophils in BALF were increased significantly in experimental group compared with the NS group , and significant difference was observed between experimental group and asthma group .The intensity of airway inflammation in experimental group was milder than that in the asthma model .Conclusions We established an eosinophilic bronchitis mice model without hyperresponsiveness successfully .Our model es-tablished a foundation for the further research in airway hyperresponsiveness .
6.An Intratracheal Challenge Murine Model of Asthma: Can Bronchial Inflammation Affect the Nose?.
Jiaxing XIE ; Yin XI ; Qingling ZHANG ; Guoqin CHEN ; Luo WEI ; Kefang LAI ; Nanshan ZHONG
Allergy, Asthma & Immunology Research 2015;7(1):76-82
PURPOSE: Extensive data support the influence of the upper airway on lower airway inflammation and pathophysiology in allergic disease. However, few studies have focused on allergic inflammation in the nose after an isolated lower airway allergen challenge, a situation that can exist clinically when human subjects breathe primarily through the mouth, as occurs when nasally congested. This study used a mouse model to investigate whether upper airway inflammation and hyperresponsiveness were induced by an isolated lower airway allergen challenge. METHODS: BALB/c mice were sensitized by systemic intraperitoneal injection of ovalbumin/saline and challenged with intratracheal ovalbumin/saline. Inflammation in the nose and lungs was assessed by cytology and histology of nasal tissues and bronchoalveolar lavage fluid (BALF), while nasal airway resistance and response were measured over 3 days post-challenge. RESULTS: Intratracheal application of an allergen in anaesthetized mice resulted in exclusive deposition in the lower airway. Compared to control animals, ovalbumin-sensitized mice after challenge showed bronchial hyperreactivity and increased IL-5 in the serum BALF, as well as eosinophil infiltration in the lungs. However, nasal histology of the ovalbumin-sensitized mice showed no increase in eosinophil infiltration. The nasal lavage fluid revealed no increase in eosinophils or IL-5, and the nasal airway resistance did not increase after challenge either. CONCLUSIONS: In a mouse allergy model, exclusive allergen challenge of the lower airway can elicit a pulmonary and systemic allergic response, but does not induce upper airway inflammatory or physiological responses.
Airway Resistance
;
Animals
;
Asthma*
;
Bronchial Hyperreactivity
;
Bronchoalveolar Lavage Fluid
;
Eosinophils
;
Estrogens, Conjugated (USP)
;
Humans
;
Hypersensitivity
;
Inflammation*
;
Injections, Intraperitoneal
;
Interleukin-5
;
Lung
;
Mice
;
Mouth
;
Nasal Lavage Fluid
;
Nose*
;
Rhinitis
7.Preparation of Peppermint Oil Moisturizing Microemulsion for Nasal Mucosa and Study on Its Mucosal Adhesion and Cilia Toxicity
Bona XUN ; Qingling BI ; Yin XIE ; Ping LI ; Li YANG ; Xiaoping BI
China Pharmacy 2019;30(12):1644-1649
OBJECTIVE: To prepare the Peppermint oil moisturizing microemulsion for nasal mucosa and survey its mucosal adhesion and cilia toxicity. METHODS: The polyoxyethylene hydrogenated castor oil was used as emulsifier to prepare the Peppermint oil moisturizing microemulsion for nasal mucosa, and the preparation technology was optimized on the basis of comprehensive score by orthogonal design. The microemulsion was characterized and the menthol content was determined by GC. The mucosal adhesion was evaluated by measuring the transport rate by cilia in vivo, and the cilia toxicity of microemulsion was evaluated by measuring the sustained movement time of cilia in vitro. RESULTS: The optimal preparation technology of self-made microemulsion was to firstly disperse the peppermint oil and the emulsifier, then add anhydrous ethanol, edible glycerin and distilled water, and stir at 1 200 r/min for 2 h. The average contents of menthol in the three batches of the microemulsion were 2.682, 2.507 and 2.496 mg/mL (RSD=2.89%,n=3), respectively. The cilia transport rates in vivo were (0.65±0.01), (0.78±0.03)and (0.92±0.04) cm/min in high-dose, medium-dose, and low-dose groups of self-made microemulsion (2.561, 0.256, 0.128 mg/mL of menthol) respectively, which were significantly lower than normal saline group and compound menthol nasal droups (P<0.05). The cilia movement time in vitro were(206.7±4.9), (226.0±13.5), (269.3±12.9)min, which were significantly longer than sodium deoxycholate group (P<0.05). CONCLUSIONS: The preparation technology of self-made microemulsion is easy-to-handle and controllable in quality. The prepared microemulsion shows good mucosal adhesion without cilia toxicity.
8.Efficacy of duplizumab in the treatment of multiple type 2 inflammatory diseases
Jiaxing XIE ; Huimin LIN ; Xiaoxian ZHANG ; Qingling ZHANG
Journal of Chinese Physician 2022;24(3):350-354
Objective:To analyze the therapeutic effect of adding interleukin (IL)-4Rα monoclonal antibody (duplizumab) to patients with multiple types of inflammatory diseases.Methods:Six patients with multiple types of inflammatory diseases who started to use duplizumab from August 2020 were enrolled. The changes of airway inflammation, lung function, sinuses computed tomography (CT), Asthma Control Questionnaire-5 (ACQ-5), Sino-Nasal Outcome Test-22 (SNOT-22), Pennsylvania Smell Identification Test (UPSIT) and Numerical Rating Scale (NRS) score before and after duplizumab treatment were retrospectively analyzed. All patients were treated with doprilumab for more than 5 months.Results:4 of the 6 patients had both severe asthma and chronic sinusitis, and 2 patients had both severe asthma, chronic sinusitis and atopic dermatitis. After treatment, the pulmonary function of 6 patients was improved, the levels of sputum eosinophils, exhaled nitric oxide and total IgE were decreased (all P<0.05), and the scores of paranasal sinus CT, ACQ-5, SNOT-22 and UPSIT were significantly improved (all P<0.05). However, 3 patients had increased peripheral blood eosinophils during the treatment. Conclusions:Duplizumab is effective for a variety of type 2 inflammatory diseases without obvious adverse reactions, and the peripheral eosinophils may increase during the treatment.
9.Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis.
Lei CHENG ; Jianjun CHEN ; Qingling FU ; Shaoheng HE ; Huabin LI ; Zheng LIU ; Guolin TAN ; Zezhang TAO ; Dehui WANG ; Weiping WEN ; Rui XU ; Yu XU ; Qintai YANG ; Chonghua ZHANG ; Gehua ZHANG ; Ruxin ZHANG ; Yuan ZHANG ; Bing ZHOU ; Dongdong ZHU ; Luquan CHEN ; Xinyan CUI ; Yuqin DENG ; Zhiqiang GUO ; Zhenxiao HUANG ; Zizhen HUANG ; Houyong LI ; Jingyun LI ; Wenting LI ; Yanqing LI ; Lin XI ; Hongfei LOU ; Meiping LU ; Yuhui OUYANG ; Wendan SHI ; Xiaoyao TAO ; Huiqin TIAN ; Chengshuo WANG ; Min WANG ; Nan WANG ; Xiangdong WANG ; Hui XIE ; Shaoqing YU ; Renwu ZHAO ; Ming ZHENG ; Han ZHOU ; Luping ZHU ; Luo ZHANG
Allergy, Asthma & Immunology Research 2018;10(4):300-353
Allergic rhinitis (AR) is a global health problem that causes major illnesses and disabilities worldwide. Epidemiologic studies have demonstrated that the prevalence of AR has increased progressively over the last few decades in more developed countries and currently affects up to 40% of the population worldwide. Likewise, a rising trend of AR has also been observed over the last 2–3 decades in developing countries including China, with the prevalence of AR varying widely in these countries. A survey of self-reported AR over a 6-year period in the general Chinese adult population reported that the standardized prevalence of adult AR increased from 11.1% in 2005 to 17.6% in 2011. An increasing number of original articles and imporclinical trials on the epidemiology, pathophysiologic mechanisms, diagnosis, management and comorbidities of AR in Chinese subjects have been published in international peer-reviewed journals over the past 2 decades, and substantially added to our understanding of this disease as a global problem. Although guidelines for the diagnosis and treatment of AR in Chinese subjects have also been published, they have not been translated into English and therefore not generally accessible for reference to non-Chinese speaking international medical communities. Moreover, methods for the diagnosis and treatment of AR in China have not been standardized entirely and some patients are still treated according to regional preferences. Thus, the present guidelines have been developed by the Chinese Society of Allergy to be accessible to both national and international medical communities involved in the management of AR patients. These guidelines have been prepared in line with existing international guidelines to provide evidence-based recommendations for the diagnosis and management of AR in China.
Adult
;
Asian Continental Ancestry Group*
;
China
;
Comorbidity
;
Developed Countries
;
Developing Countries
;
Diagnosis*
;
Epidemiologic Studies
;
Epidemiology
;
Global Health
;
Humans
;
Hypersensitivity*
;
Prevalence
;
Rhinitis, Allergic*
10.Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies.
Zhenan DENG ; Meiling JIN ; Changxing OU ; Wei JIANG ; Jianping ZHAO ; Xiaoxia LIU ; Shenghua SUN ; Huaping TANG ; Bei HE ; Shaoxi CAI ; Ping CHEN ; Penghui WU ; Yujing LIU ; Jian KANG ; Yunhui ZHANG ; Mao HUANG ; Jinfu XU ; Kewu HUANG ; Qiang LI ; Xiangyan ZHANG ; Xiuhua FU ; Changzheng WANG ; Huahao SHEN ; Lei ZHU ; Guochao SHI ; Zhongmin QIU ; Zhongguang WEN ; Xiaoyang WEI ; Wei GU ; Chunhua WEI ; Guangfa WANG ; Ping CHEN ; Lixin XIE ; Jiangtao LIN ; Yuling TANG ; Zhihai HAN ; Kian Fan CHUNG ; Qingling ZHANG ; Nanshan ZHONG
Chinese Medical Journal 2023;136(2):230-232